Klinik und Therapie des Steroidglaukoms

Zusammenfassung

Bei einer Steroidresponse kommt es nach topischer oder systemischer Anwendung von Steroiden zu einer Vermehrung von extrazellulärer Matrix im Trabekelmaschenwerk und dadurch zu einer Erhöhung des Kammerwasserabflusswiderstands. 30–40 % der Normalbevölkerung sind Steroidresponder. Etwa 5 % entwickeln Anstiege des intraokularen Druckes (IOD) von > 15 mmHg. Diese Patienten werden als „High Responder“ bezeichnet. Bei Patienten mit primärem Offenwinkelglaukom (POWG) liegt der Anteil der Steroidresponder bei etwa 90 %. Das Ausmaß der Steroidresponse ist abhängig von Art und Dauer der Anwendung eines Steroids. Die höchste IOD-steigernde Potenz hat Dexamethason. Mögliche Differenzialdiagnosen sind POWG, okuläre Hypertension, Normaldruckglaukom, Pseudoexfoliationsglaukom und Sekundärglaukome anderer Genese. Für die Diagnosestellung ist eine detaillierte Anamnese wichtig. Beweisend ist ein Rückgang des IOD nach Absetzen der Steroide. Die Therapie eines Steroidglaukoms umfasst neben der topischen Anwendung von Antiglaukomatosa unter anderem fistulierende Eingriffe, Trabekulotomie und Lasereingriffe. Bisher sind jedoch für das Steroidglaukom wenig vergleichende Studien zu unterschiedlichen operativen Verfahren publiziert worden. Nach Anwendung von intravitreal oder subkonjunktival applizierten Steroiden kommt bei therapieresistenter IOD-Steigerung auch eine operative Entfernung der Steroide aus dem Auge in Betracht. Eine Gentherapie des Steroidglaukoms wird derzeit noch erforscht.

Abstract

In steroid responders, topical or systemic application of steroids leads to extracellular deposits in the trabecular meshwork which increase trabecular meshwork outflow resistance. 30–40 % of the normal population are steroid responders. About 5 % develop an intraocular pressure (IOP) rise of > 15 mmHg. These patients are termed “high responders”. In patients with primary open angle glaucoma (POAG), the proportion of steroid responders sums up to 90 %. The extent of steroid response depends on the kind of steroid used and on the duration of its administration. Dexamethasone has the highest IOP increasing potency. Differential diagnoses are POAG, ocular hypertension, normal tension glaucoma, pseudoexfoliation glaucoma and secondary glaucoma due to different reasons. To make the diagnosis, a detailed anamnesis is crucial. A recompensated IOP after the end of steroid use proves the diagnosis. The treatment of steroid glaucoma includes topical antiglaucoma medications, glaucoma filtration surgery, trabeculotomy, and laser surgery. So far, only few comparative studies on different treatment options have been published on steroid glaucoma. In some cases of therapy-resistant IOP increases following intravitreal or subconjunctival steroid administration, operative removal of the steroids can be considered. A gene therapy treatment of steroid glaucoma is still a topic of research.

Schlüsselwörter

Glaukom - Pharmakologie - Steroide

Key words

glaucoma - pharmacology - steroids

• Literatur

• 1 Lütjen-Drecoll E. Functional morphology of the trabecular meshwork in primate eyes. Prog Retin Eye Res 1999; 18: 91-119
• 2 Tamm ER. The trabecular meshwork outflow pathways: structural and functional aspects. Exp Eye Res 2009; 88: 648-655
• 3 Tektas OY, Lütjen-Drecoll E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp Eye Res 2009; 88: 769-775
• 4 Clark AF, Wordinger RJ. The role of steroids in outflow resistance. Exp Eye Res 2009; 88: 752-759
• 5 Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 1990; 31: 2568-2571
• 6 Steely HT, Browder SL, Julian MB et al. The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1992; 33: 2242-2250
• 7 Clark AF, Wilson K, McCartney MD et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1994; 35: 281-294
• 8 Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006; 20: 407-416
• 9 Armaly MF, Becker B. Intraocular pressure response to topical corticosteroids. Fed Proc 1965; 24: 1274-1278
• 10 Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics. II. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 1963; 70: 492-499
• 11 Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964; 57: 543-551
• 12 Jonas JB, Degenring RF, Kreissig I et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112: 593-598
• 13 Jones 3rd R, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17: 163-167
• 14 Gaston H, Absolon MJ, Thurtle OA et al. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983; 67: 487-490
• 15 Cantrill HL, Palmberg PF, Zink HA et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol 1975; 79: 1012-1017
• 16 Leibowitz HM, Bartlett JD, Rich R et al. Intraocular pressure-raising potential of 1.0 % rimexolone in patients responding to corticosteroids. Arch Ophthalmol 1996; 114: 933-937
• 17 Weinreb RN, Polansky JR, Kramer SG et al. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci 1985; 26: 170-175
• 18 Inatani M, Iwao K, Kawaji T et al. Intraocular pressure elevation after injection of triamcinolone acetonide: a multicenter retrospective case-control study. Am J Ophthalmol 2008; 145: 676-681
• 19 Singh IP, Ahmad SI, Yeh D et al. Early rapid rise in intraocular pressure after intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2004; 138: 286-287
• 20 Mayer WJ, Remy M, Wolf A et al. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema. Ophthalmologica 2012; 228: 110-116
• 21 Haller JA, Bandello F, Belfort jr. R et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460
• 22 Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol 1976; 95: 207-208
• 23 Akingbehin AO. Corticosteroid-induced ocular hypertension. II. An acquired form. Br J Ophthalmol 1982; 66: 541-545
• 24 Spiers F. Topical steroids and intraocular pressure. II. An evaluation of the intraocular pressure in 93 outpatients divided according to their response to monocular steroid provocation and studies on the reaction of the control eye. Acta Ophthalmol (Copenh) 1965; 43: 812-820
• 25 Garbe E, LeLorier J, Boivin JF et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722-727
• 26 Bernstein HN, Schwartz B. Effects of long-term systemic steroids on ocular pressure and tonographic values. Arch Ophthalmol 1962; 68: 742-753
• 27 Gehlen M, Canto AP, Skare TL et al. Short-term, high-dose systemic steroids and intraocular pressure. Can J Ophthalmol 2009; 44: 465
• 28 Krist D, Cursiefen C, Jünemann A. Transitorische intrathorakale und -abdominale Druckerhöhung in der Anamnese von 64 Patienten mit Normaldruckglaukomen. Klin Monatsbl Augenheilkd 2001; 218: 209-213
• 29 Schlötzer-Schrehardt U, Naumann GO. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006; 141: 921-937
• 30 Agrawal S, Agrawal J, Agrawal TP. Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol 2005; 139: 575-576
• 31 Okka M, Bozkurt B, Kerimoglu H et al. Control of steroid-induced glaucoma with surgical excision of sub-Tenon triamcinolone acetonide deposits: a clinical and biochemical approach. Can J Ophthalmol 2010; 45: 621-626
• 32 Rhee DJ, Peck RE, Belmont J et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006; 90: 999-1003
• 33 Breusegem C, Vandewalle E, Van CJ et al. Predictive value of a topical dexamethasone provocative test before intravitreal triamcinolone acetonide injection. Invest Ophthalmol Vis Sci 2009; 50: 573-576
• 34 Iwao K, Inatani M, Tanihara H. Success rates of trabeculotomy for steroid-induced glaucoma: a comparative, multicenter, retrospective cohort study. Am J Ophthalmol 2011; 151: 1047-1056
• 35 Krishnan R, Kumar N, Wishart PK. Viscocanalostomy for refractory glaucoma secondary to intravitreal triamcinolone acetonide injection. Arch Ophthalmol 2007; 125: 1284-1286
• 36 Ricci F, Missiroli F, Parravano M. Argon laser trabeculoplasty in triamcinolone acetonide induced ocular hypertension refractory to maximal medical treatment. Eur J Ophthalmol 2006; 16: 756-757
• 37 Viola F, Morescalchi F, Staurenghi G. Argon laser trabeculoplasty for intractable glaucoma following intravitreal triamcinolone. Arch Ophthalmol 2006; 124: 133-134
• 38 Rubin B, Taglienti A, Rothman RF et al. The effect of selective laser trabeculoplasty on intraocular pressure in patients with intravitreal steroid-induced elevated intraocular pressure. J Glaucoma 2008; 17: 287-292
• 39 Gerometta R, Spiga MG, Borras T et al. Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci 2010; 51: 3042-3048
• 40 Spiga MG, Borras T. Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma. Invest Ophthalmol Vis Sci 2010; 51: 3029-3041